NCT01975077View on ClinicalTrials.gov

A Phase Ib Study of Fruquintinib in 3rd Line mCRC

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

October 31, 2014

Conditions
Colorectal Cancer
Interventions
DRUG

fruquintinib

Fruquintinib is a capsule in the form of 1mg and 5mg, orally, daily

Trial Locations (2)

200032

Fudan University Cancer Center, Shanghai

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
collaborator

Fudan University

OTHER

collaborator

Sun Yat-sen University

OTHER

lead

Hutchison Medipharma Limited

INDUSTRY

NCT01975077 - A Phase Ib Study of Fruquintinib in 3rd Line mCRC | Biotech Hunter | Biotech Hunter